# US Helicobacter Pylori Test Market

> US Helicobacter Pylori Test Market Research Report: Size, Share, Trend Analysis By Types (Non-endoscopic, Endoscopic), By Technology (Immunoassays, Point of care, Molecular Diagnostics) and By End Users (Hospitals & clinics, Diagnostic laboratories, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.7%
- **2024:** $ 582.21 Million
- **2025:** $ 615.4 Million
- **2035:** $ 1,071.5 Million
- **Key Players:** Abbott Laboratories (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd (CH), Siemens Healthineers (DE), Becton, Dickinson and Company (US), Halyard Health (US), Bio-Rad Laboratories (US), Meridian Bioscience, Inc. (US)

**Report ID:** MRFR/HC/17829-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-helicobacter-pylori-test-market-19376

---

## Market Summary

## **US Helicobacter Pylori Test Market Overview**

As per MRFR analysis, the US Helicobacter Pylori Test Market Size was estimated at 748.67 (USD Million) in 2023. The US Helicobacter Pylori Test Market Industry is expected to grow from 830(USD Million) in 2024 to 1,500 (USD Million) by 2035. The US Helicobacter Pylori Test Market CAGR (growth rate) is expected to be around 5.527% during the forecast period (2025 - 2035).

### **Key US Helicobacter Pylori Test Market Trends Highlighted**

The US Helicobacter Pylori Test Market is witnessing a notable shift towards non-invasive testing methods, which is driven by the increasing demand for patient comfort and convenience. The rise in awareness regarding the health implications of Helicobacter Pylori infection, such as peptic ulcers and gastric cancer, is encouraging patients to seek testing solutions promptly. Current trends show a preference for rapid diagnostic tests that offer results in a shorter timeframe, enhancing both clinical workflow efficiency and patient experience. 

Furthermore, a growing emphasis on preventive healthcare is propelling the demand for routine testing in at-risk demographics, including individuals with a history of gastrointestinal issues.There are significant opportunities to be captured in the US market, particularly through innovations in testing technology. Manufacturers are exploring next-generation testing kits that combine higher accuracy with ease of use. Collaborations with healthcare providers to facilitate widespread screening programs can also enhance market access and education regarding Helicobacter Pylori. 

The integration of telehealth services for consultation and testing follow-up presents an additional avenue for increasing testing rates and providing support to patients remotely. Recent trends also indicate a rising interest in personalized medicine, where treatment plans for Helicobacter Pylori are tailored based on specific patient profiles.This approach highlights the importance of understanding genetic factors and microbial resistance patterns, ultimately leading to more effective management of the infection. Public health initiatives in the US are emphasizing the importance of early detection and treatment to mitigate long-term health consequences, further fostering a proactive approach within the healthcare system.

As such, the US Helicobacter Pylori Test Market is evolving rapidly in response to these various healthcare dynamics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Helicobacter Pylori Test Market Drivers**

### **Rising Prevalence of Helicobacter Pylori Infection**

The increasing incidence of Helicobacter Pylori infections among the US population serves as a significant driver for the US Helicobacter Pylori Test Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 30 to 40 percent of adults in the United States are estimated to be infected with Helicobacter Pylori at some point in their lives. This high prevalence creates a growing demand for effective diagnostic testing.Furthermore, the American Gastroenterological Association indicates that H.

Pylori infection is a major cause of peptic ulcers and has been linked to gastric cancer, driving the need for early detection and treatment solutions. Medical professionals, including those affiliated with the American Gastroenterological Association, emphasize the importance of testing, especially for patients presenting symptoms indicative of gastrointestinal distress.Therefore, the rising number of diagnosed cases is anticipated to substantially boost the demand for Helicobacter Pylori tests in the US market, directly correlating with market growth.

### **Advancements in Diagnostic Technology**

The continuous advancements in diagnostic technology significantly contribute to the growth of the US Helicobacter Pylori Test Market Industry. Innovations such as non-invasive breath tests, stool antigen tests, and advanced endoscopic biopsy methods have improved the accuracy and reliability of H. Pylori detection. The American Society for Gastrointestinal Endoscopy (ASGE) has published guidelines endorsing new diagnostic technologies that allow for quicker results and higher patient satisfaction.The growing penetration of these advanced diagnostic methodologies has led to an increase in the number of healthcare facilities adopting H. Pylori testing.

This trend is encouraged further by support from medical technology companies that are developing user-friendly, efficient testing tools tailored for clinical environments in the US. As hospitals and diagnostic centers increasingly rely on innovative testing options, the US Helicobacter Pylori Test Market is projected to experience robust growth.

### **Increased Focus on Preventative Healthcare Initiatives**

There is an increasing emphasis on preventative healthcare initiatives across the United States, which is a vital driver for the US Helicobacter Pylori Test Market Industry. The US government and healthcare organizations, such as the National Institutes of Health (NIH), have implemented comprehensive public health programs aimed at raising awareness about gastrointestinal diseases linked to Helicobacter Pylori. These initiatives cater to educating the public on the risks associated with untreated infections, thereby highlighting the importance of testing.Moreover, as healthcare policies shift toward valuing preventative care, there is a growing trend among insurance providers to cover H.

Pylori testing as part of routine health check-ups, especially for at-risk populations. This growing focus on preventative measures is likely to increase the number of individuals undergoing H. Pylori testing, thereby propelling market growth in the US.

## **US Helicobacter Pylori Test Market Segment Insights**

### **Helicobacter Pylori Test Market Type Insights**

The US Helicobacter Pylori Test Market is characterized by its diverse types that cater to various diagnostic needs, primarily categorized into Non-endoscopic and Endoscopic methods. Non-endoscopic tests, which typically include breath tests, stool antigen tests, and serology tests, are favored for their non-invasive nature, making them more accessible and preferable for patients. This group serves a significant portion of the population as it is easier to administer and allows for quicker screening without the discomfort associated with invasive procedures.

In contrast, Endoscopic testing, often viewed as the gold standard for diagnosing Helicobacter Pylori, involves more invasive techniques such as biopsy and is crucial in patients who present with severe symptoms or conditions like gastrointestinal bleeding. 

The importance of Endoscopic procedures is underscored by their accuracy in detecting not only Helicobacter Pylori but also other gastrointestinal disorders, thus ensuring comprehensive patient assessment. As the population in the US increasingly becomes aware of gastrointestinal health, the demand for both testing types continues to grow. The ongoing advancements in technology further enhance the efficiency and sensitivity of these tests, thereby improving patient outcomes and diagnosis accuracy. Furthermore, factors such as the rising prevalence of Helicobacter Pylori-related diseases, coupled with the growing emphasis on preventive healthcare, contribute to the evolving landscape of the US Helicobacter Pylori Test Market. 

However, challenges remain, including variations in test accuracy, accessibility to advanced diagnostic tools in rural areas, and the need for continuous education around the importance of testing. Overall, the Type segmentation within the US Helicobacter Pylori Test Market highlights a balanced interplay between patient comfort and procedural accuracy, driving the growth and evolution of testing methodologies in addressing Helicobacter Pylori infections across the nation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Helicobacter Pylori Test Market Technology Insights**

The US Helicobacter Pylori Test Market, focusing on the Technology aspect, showcases a diverse range of testing methodologies, each playing a distinct role in diagnosing and managing Helicobacter pylori infections. Immunoassays are widely utilized due to their effectiveness in rapid testing and ease of use, making them an essential tool in primary care settings. Point of care technology testing continues to gain traction, allowing for immediate results that enhance patient management by facilitating timely treatment decisions, thus improving outcomes.

Molecular Diagnostics, recognized for their high specificity and sensitivity, are increasingly significant in complex cases where traditional methods may not suffice.This segment continues to evolve, benefiting from advancements in technology and R&D initiatives aimed at improving diagnostic accuracy. The growing prevalence of Helicobacter pylori infections in the US has intensified the demand for innovative testing solutions, further propelling the development of these technologies. Collectively, these segments are pivotal in shaping the US Helicobacter Pylori Test Market, addressing clinical needs while also contributing to overall public health efforts against gastrointestinal diseases associated with H.pylori.

### **Helicobacter Pylori Test Market End User Insights**

The US Helicobacter Pylori Test Market is significantly influenced by its End User segments, which include Hospitals and clinics, Diagnostic laboratories, and Others. Hospitals and clinics are crucial as they typically serve as primary healthcare providers, conducting a high volume of tests due to patient inflow related to gastrointestinal issues. These facilities leverage advanced diagnostic tools to ensure accurate and timely detection, driving demand in the market.

Diagnostic laboratories play a vital role by specializing in various testing methodologies, thus enabling a wider range of testing options that cater to specific patient needs.Such laboratories enhance patient care through accurate and efficient testing services. The “Others” segment encompasses various healthcare settings, contributing to market flexibility and accessibility. Overall, the diverse End User landscape is essential for fulfilling the increasing demand for effective Helicobacter Pylori testing solutions, especially in an era where gastrointestinal health is receiving heightened attention across the US.

Strategies aimed at improving awareness and expanding testing capabilities in these segments are expected to further catalyze market growth.

## **US Helicobacter Pylori Test Market Key Players and Competitive Insights**

The US Helicobacter Pylori Test Market is characterized by a dynamic environment driven by advancements in diagnostic technologies and increased awareness regarding the prevalence of Helicobacter pylori infections. As healthcare providers and patients prioritize accurate diagnosis and effective management of gastrointestinal disorders, the competition within this market has intensified. A variety of testing methods are offered, including serological tests, urea breath tests, and stool antigen tests, catering to diverse patient needs and clinical settings.

This competitive landscape is shaped by the presence of established companies, emerging players, and the introduction of innovative solutions that address both current and evolving market demands. The market dynamics are influenced by factors such as regulatory approvals, reimbursement policies, and ongoing research focused on enhancing diagnostic accuracy and patient outcomes.

Hologic has positioned itself as a strong competitor in the US Helicobacter Pylori Test Market by leveraging its expertise in molecular diagnostics and other advanced testing methodologies. The company emphasizes maintaining high-quality standards for its products, which are designed to deliver reliable results that aid clinicians in making informed decisions regarding patient treatment. Hologic’s strength lies in its comprehensive portfolio of diagnostic solutions that support gastrointestinal health, allowing the company to cater to a wide range of clinical applications.

Additionally, its established relationship with healthcare providers and presence in various healthcare settings solidify Hologic’s competitive edge, enhancing its capability to penetrate the market effectively while also promoting innovations that improve diagnostic precision.

Eiken Chemical has carved out a significant role in the US Helicobacter Pylori Test Market through its commitment to offering dependable diagnostic solutions that address critical healthcare challenges. The company's portfolio includes key products such as the immunoassay and molecular diagnostic kits that enable quick and accurate detection of Helicobacter pylori infections. Eiken Chemical's strengths lie in its strong emphasis on research and development, which allows for the continuous improvement of its offerings. The company has also pursued strategic partnerships and collaborations that bolster its market presence and enhance its product range within the US.

Moreover, Eiken Chemical actively participates in educational initiatives that promote awareness of Helicobacter pylori infections, strengthening its position in the market while also supporting healthcare professionals in managing these infections effectively.

### **Key Companies in the US Helicobacter Pylori Test Market Include**

### **US Helicobacter Pylori Test Market Industry Developments**

Recent developments in the US Helicobacter Pylori Test Market indicate significant growth and advancements. Companies such as Hologic and Abbott Laboratories have been pushing forward with new diagnostic technologies, enhancing the accuracy and speed of H. pylori testing. In September 2022, Quidel Corporation announced an expansion of its product portfolio, focusing on point-of-care testing solutions that are crucial in more accessible treatment options for H. pylori-related conditions. Additionally, in June 2023, BioRad Laboratories reported an increase in demand for its testing kits, reflecting the growing awareness of gastric health in the US population.

Recent mergers and acquisitions have also been a defining aspect; for instance, in August 2023, Siemens Healthineers acquired a specialized diagnostics company to enhance their capabilities in gastrointestinal testing, which encompasses H. pylori diagnostics. Growth in the market can be attributed to rising incidences of digestive disorders linked to H. pylori and an increased emphasis on rapid diagnosis. Investments in Research and Development are projected to heighten innovation in testing methods, further driving the market forward. Over the past 2-3 years, concerted efforts by these companies have led to significant improvements in testing accuracy and patient outcomes.

## **US Helicobacter Pylori Test Market Segmentation Insights**

### **Helicobacter Pylori Test Market Type Outlook**

### **Helicobacter Pylori Test Market Technology Outlook**

### **Helicobacter Pylori Test Market End User Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The increase in healthcare expenditure in the US is likely to bolster the helicobacter pylori-test market. As individuals and families allocate more resources towards health services, there is a corresponding rise in the demand for diagnostic tests, including those for H. pylori. According to recent data, healthcare spending in the US has been projected to grow at an annual rate of 5.4%, reaching approximately $6 trillion by 2027. This financial commitment to health services may lead to greater accessibility and affordability of testing options, encouraging more patients to seek diagnosis and treatment for H. pylori infections. Consequently, the helicobacter pylori-test market stands to gain from this upward trend in healthcare investment.

### Growing Focus on Preventive Healthcare

The shift towards preventive healthcare in the US is a significant factor driving the helicobacter pylori-test market. With an increasing emphasis on early detection and management of health conditions, healthcare providers are advocating for routine screening for H. pylori, especially in high-risk populations. This proactive approach is expected to lead to a higher uptake of testing services, as patients become more engaged in their health management. The market could see a notable increase in demand as healthcare policies evolve to support preventive measures, potentially reducing the burden of gastrointestinal diseases associated with H. pylori. As a result, the helicobacter pylori-test market may benefit from this growing trend in preventive healthcare.

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic testing are significantly influencing the helicobacter pylori-test market. The introduction of non-invasive testing methods, such as breath tests and stool antigen tests, has made it easier for patients to undergo screening. These advancements not only enhance patient comfort but also improve the accuracy and speed of diagnosis. For instance, the breath test has shown a sensitivity of over 90% in detecting H. pylori infections. As healthcare facilities adopt these advanced technologies, the market is likely to experience growth, driven by the increasing preference for rapid and reliable testing solutions. Furthermore, the integration of digital health technologies may facilitate remote testing and monitoring, further propelling market expansion.

### Increasing Prevalence of Helicobacter Pylori Infections

The rising incidence of Helicobacter pylori infections in the US is a crucial driver for the helicobacter pylori-test market. Studies indicate that approximately 30-40% of the US population may be infected with this bacterium, which is linked to various gastrointestinal disorders, including peptic ulcers and gastric cancer. As awareness of these health issues grows, the demand for accurate and efficient testing methods is likely to increase. This trend is further supported by healthcare providers emphasizing the importance of early detection and treatment, which could potentially reduce the long-term healthcare costs associated with untreated infections. Consequently, the helicobacter pylori-test market is expected to expand as more individuals seek testing to confirm or rule out infections.

### Increased Collaboration Between Healthcare Providers and Laboratories

The growing collaboration between healthcare providers and diagnostic laboratories is a notable driver for the helicobacter pylori-test market. As healthcare systems strive for improved patient outcomes, partnerships are being formed to streamline testing processes and enhance the quality of care. These collaborations often result in the development of integrated testing pathways, which can facilitate quicker diagnosis and treatment initiation for H. pylori infections. Additionally, shared resources and expertise can lead to innovations in testing methodologies, further advancing the market. This synergy between providers and laboratories is likely to foster a more efficient healthcare environment, ultimately benefiting the helicobacter pylori-test market.

## Future Outlook

The [Helicobacter Pylori Test Market](https://www.marketresearchfuture.com/reports/helicobacter-pylori-test-market-8497) is projected to grow at a 5.7% CAGR from 2025 to 2035, driven by increasing prevalence of gastrointestinal disorders and advancements in diagnostic technologies.

**New opportunities:**

- Development of rapid point-of-care testing kits for remote diagnostics. Expansion of telehealth services integrating H. pylori testing. Partnerships with pharmaceutical companies for bundled treatment solutions.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Test Type: Non-endoscopic (Largest) vs. Endoscopic (Fastest-Growing)

In the US helicobacter pylori-test market, Non-endoscopic testing holds the largest market share, primarily due to its ease of use and cost-effectiveness, making it a preferred choice among healthcare providers and patients alike. This method has been widely adopted for its non-invasive approach, which has increased its penetration and utilization in various clinical settings, ensuring it remains a key player in the market. On the other hand, Endoscopic testing is witnessing the fastest growth, driven by technological advancements and the increasing prevalence of gastrointestinal diseases. This method offers enhanced diagnostic accuracy and provides direct visualization, which is crucial for effective treatment planning. The shift towards more precise testing protocols among healthcare professionals is fueling the demand for Endoscopic tests, thereby accelerating its growth trajectory in the market.

Testing Method: Non-endoscopic (Dominant) vs. Endoscopic (Emerging)

Non-endoscopic testing is the dominant method in the US helicobacter pylori-test market due to its user-friendly nature and affordability, catering to a broad demographic of patients. This segment includes various methodologies such as antigen tests and breath tests, which are increasingly preferred because they require less invasive procedures, leading to higher patient compliance. Conversely, Endoscopic testing is emerging as a vital alternative, particularly for cases where a more thorough diagnostic approach is needed. While it involves more complex procedures, the accuracy and ability to detect associated conditions position it as an appealing option in specialized medical settings. Both segments highlight the diverse requirements within the market, reflecting a balance between patient convenience and diagnostic precision.

### By Technology: Immunoassays (Largest) vs. Molecular Diagnostics (Fastest-Growing)

In the US helicobacter pylori-test market, Immunoassays dominate the market share due to their widespread acceptance and efficacy in detecting H. pylori infections. These tests are user-friendly and relatively inexpensive, making them a preferred choice for both healthcare professionals and patients. Point of care testing is also gaining traction, but it still lags behind the Immunoassays in market share. Meanwhile, Molecular Diagnostics is emerging with a growing share, primarily driven by the need for accuracy in testing and faster result delivery. The growth trends in this segment reveal a shift towards more advanced testing methodologies, with Molecular Diagnostics showing the highest growth rate. This increase is attributed to technological advancements that enhance the precision and speed of H. pylori detection. Furthermore, the rise in awareness regarding gastrointestinal disorders and the importance of early detection contribute to the increasing adoption of these technologies in the market. As healthcare providers seek more reliable and efficient testing solutions, the demand for Molecular Diagnostics is expected to continue its upward trajectory.

Immunoassays: Dominant vs. Molecular Diagnostics: Emerging

Immunoassays remain the dominant technology in the US helicobacter pylori-test market due to their established reliability and cost-effectiveness. They facilitate rapid testing, which aligns with clinical needs for swift diagnosis and treatment decisions. In contrast, Molecular Diagnostics, characterized by high sensitivity and specificity, represent the emerging technology, catering to a niche yet expanding market segment. These tests utilize sophisticated techniques, such as PCR, to provide accurate results, addressing the evolving healthcare standards for infection management. As the healthcare landscape continues to prioritize precision medicine, both segment values will play vital roles, with Immunoassays maintaining their stronghold while Molecular Diagnostics positions itself as the future of testing.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The US helicobacter pylori-test market is primarily dominated by hospitals and clinics, which account for a significant share of the overall market. This segment benefits from high patient footfalls and the integration of advanced testing technologies within these institutions. On the other hand, diagnostic laboratories, while smaller in comparison, are witnessing a rapid increase in demand due to their capacity to provide specialized services and quicker turnaround times for test results. Growth trends within the segment are driven by rising awareness about helicobacter pylori infections and their links to various gastrointestinal diseases. The convenience and efficiency provided by diagnostic laboratories cater well to this demand, making them the fastest-growing segment. Additionally, technological advancements and the increasing prevalence of related health issues continue to bolster market growth, emphasizing the need for accessible testing options across the healthcare landscape.

Hospitals & Clinics (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals and clinics represent the dominant force in the US helicobacter pylori-test market, offering comprehensive care and extensive resources for diagnosis and treatment. Their established infrastructure allows for the integration of advanced testing methodologies, ensuring accurate results and robust patient management. In contrast, diagnostic [laboratories](../../../reports/dental-laboratories-market-9282) are emerging as significant players, providing focused services that prioritize efficiency and speed in processing tests. Their adaptability to new technologies, coupled with lower overhead costs compared to larger medical institutions, gives them a competitive edge. This duality in market positioning illustrates the evolving dynamics, where hospitals and clinics remain foundational, while diagnostic laboratories capture the growing demand for specialized testing services.

## Competitive Benchmarking

The helicobacter pylori-test market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on enhancing diagnostic accuracy. Key players such as Abbott Laboratories (US), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche Ltd (CH) are at the forefront, leveraging their technological capabilities to drive growth. Abbott Laboratories (US) emphasizes innovation in its diagnostic solutions, aiming to enhance patient outcomes through advanced testing methodologies. Meanwhile, Thermo Fisher Scientific (US) focuses on expanding its product portfolio and enhancing its market presence through strategic acquisitions and collaborations, which collectively contribute to a dynamic competitive environment. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market appears moderately fragmented, with several players vying for market share while also collaborating to enhance their offerings. This competitive structure allows for a diverse range of products and services, catering to varying customer needs and preferences. In October 2025, Abbott Laboratories (US) announced the launch of a new rapid diagnostic test for helicobacter pylori, which is expected to significantly reduce the time required for diagnosis. This strategic move not only enhances Abbott's product offerings but also positions the company as a leader in rapid testing solutions, potentially increasing its market share in the US. The introduction of this test aligns with the growing demand for quick and accurate diagnostics in the healthcare sector. In September 2025, Thermo Fisher Scientific (US) expanded its partnership with a leading healthcare provider to enhance the distribution of its helicobacter pylori testing kits. This collaboration is likely to improve accessibility to advanced diagnostic tools, thereby increasing the company's footprint in the market. By strengthening its distribution channels, Thermo Fisher aims to capitalize on the rising prevalence of helicobacter pylori infections and the corresponding demand for effective testing solutions. In August 2025, F. Hoffmann-La Roche Ltd (CH) unveiled a new digital platform designed to streamline the testing process for helicobacter pylori. This platform integrates AI technology to assist healthcare professionals in interpreting test results more efficiently. The strategic importance of this initiative lies in its potential to enhance diagnostic accuracy and reduce the burden on healthcare systems, thereby reinforcing Roche's commitment to innovation in diagnostics. As of November 2025, the competitive trends in the helicobacter pylori-test market are increasingly influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative solutions that address the complexities of modern healthcare needs.

## Recent News & Developments

Recent developments in the US Helicobacter Pylori Test Market indicate significant growth and advancements. Companies such as Hologic and Abbott Laboratories have been pushing forward with new diagnostic technologies, enhancing the accuracy and speed of H. pylori testing. In September 2022, Quidel Corporation announced an expansion of its product portfolio, focusing on point-of-care testing solutions that are crucial in more accessible treatment options for H. pylori-related conditions. Additionally, in June 2023, BioRad Laboratories reported an increase in demand for its testing kits, reflecting the growing awareness of gastric health in the US population.

Recent mergers and acquisitions have also been a defining aspect; for instance, in August 2023, Siemens Healthineers acquired a specialized diagnostics company to enhance their capabilities in gastrointestinal testing, which encompasses H. pylori diagnostics. Growth in the market can be attributed to rising incidences of digestive disorders linked to H. pylori and an increased emphasis on rapid diagnosis. Investments in Research and Development are projected to heighten innovation in testing methods, further driving the market forward. Over the past 2-3 years, concerted efforts by these companies have led to significant improvements in testing accuracy and patient outcomes.

## Report Scope

| MARKET SIZE 2024 | 582.21(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 615.4(USD Million) |
| MARKET SIZE 2035 | 1071.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd (CH), Siemens Healthineers (DE), Becton, Dickinson and Company (US), Halyard Health (US), Bio-Rad Laboratories (US), Meridian Bioscience, Inc. (US) |
| Segments Covered | Test Type, Technology, End User |
| Key Market Opportunities | Advancements in non-invasive testing methods enhance patient compliance in the helicobacter pylori-test market. |
| Key Market Dynamics | Rising demand for non-invasive testing methods drives innovation in the helicobacter pylori-test market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US helicobacter pylori-test market in 2024?**
A: The market valuation was $582.21 Million in 2024.

**Q: What is the projected market valuation for the US helicobacter pylori-test market by 2035?**
A: The projected valuation for 2035 is $1071.5 Million.

**Q: What is the expected CAGR for the US helicobacter pylori-test market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.7% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US helicobacter pylori-test market?**
A: Key players include Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Becton, Dickinson and Company, Halyard Health, Bio-Rad Laboratories, and Meridian Bioscience, Inc.

**Q: What are the two main test types in the US helicobacter pylori-test market and their valuations?**
A: The two main test types are Non-endoscopic, valued between $350.0 Million and $650.0 Million, and Endoscopic, valued between $232.21 Million and $421.5 Million.

**Q: What technologies are utilized in the US helicobacter pylori-test market?**
A: Technologies include Immunoassays, valued between $200.0 Million and $400.0 Million, Point of Care, valued between $150.0 Million and $300.0 Million, and Molecular Diagnostics, valued between $232.21 Million and $371.5 Million.

**Q: What are the primary end users of the US helicobacter pylori-test market?**
A: Primary end users include Hospitals & Clinics, valued between $349.32 Million and $615.12 Million, Diagnostic Laboratories, valued between $174.66 Million and $348.06 Million, and Others, valued between $58.23 Million and $108.32 Million.

**Q: How does the market for Immunoassays compare to other technologies in the US helicobacter pylori-test market?**
A: Immunoassays, valued between $200.0 Million and $400.0 Million, are a significant segment, though Molecular Diagnostics shows a competitive valuation between $232.21 Million and $371.5 Million.

**Q: What trends are influencing the growth of the US helicobacter pylori-test market?**
A: Trends influencing growth include advancements in diagnostic technologies and increasing awareness of helicobacter pylori-related health issues.

**Q: What is the potential for growth in the US helicobacter pylori-test market by 2035?**
A: The market appears poised for growth, potentially reaching $1071.5 Million by 2035, driven by a CAGR of 5.7%.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-helicobacter-pylori-test-market-19376*